Continuous Glucose Monitoring Systems for Type 1 Diabetes Mellitus

Overview

Study Title: Continuous glucose monitoring systems for type 1 diabetes mellitus
Authors: Miranda Langendam, Yoeri M. Luijfa, Lotty Hooft, J. Hans DeVries, Aart H. Mudde, Rob JPM Scholten
Version Published: January 18, 2012
Source: Cochrane Database of Systematic Reviews

Type 1 Diabetes Management: Involves self-monitoring of blood glucose to optimize glycemic control.
Continuous Glucose Monitoring (CGM): Measures interstitial fluid glucose levels, offering semi-continuous glucose data and recognizing fluctuations not easily detected by conventional fingerprick self-monitoring.
Types of CGM Systems:
- Retrospective systems
- Realtime systems (provide current glucose concentration on display)

To assess the effects of CGM systems compared to conventional self-monitoring of blood glucose (SMBG) in type 1 diabetes patients.

Databases Searched: Cochrane Library, MEDLINE, EMBASE, CINAHL
Selection Criteria: Randomized controlled trials comparing CGM with SMBG in type 1 diabetes patients.
Primary Outcomes: Glycemic control (HbA1c levels) and health-related quality of life.
Secondary Outcomes: Adverse events, complications, costs.

Included Studies: 22 RCTs with 2883 patients.
Main Findings:
- Significant decline in HbA1c for CGM users starting insulin pump therapy compared to MDI and SMBG users.
- Mean difference in HbA1c: 0.7% reduction for CGM with pump, 0.2% for CGM alone.
- Increased risk of hypoglycemia for CGM users; however, confidence intervals include a range of outcomes.
- No significant difference in health-related quality of life between CGM and SMBG users.
Adverse Events: Severe hypoglycemia and ketoacidosis occurred infrequently.
Other Outcomes: Diabetes complications, death, and costs not measured.

Limited evidence supporting CGM effectiveness in children, adults, and poorly controlled diabetes patients.
Largest improvements observed in sensor-augmented insulin pump users.
Compliance with CGM use is critical for improving glycemic control.

Type 1 Diabetes: Condition causing loss of insulin production, leading to elevated glucose levels and potential complications.
CGM Systems: Offer a more comfortable alternative to fingerpricks, providing continuous glucose data and trends.
Study Results: Decrease in HbA1c with CGM; low occurrence of adverse events like severe hypoglycemia and ketoacidosis.
Note: No data on pregnant women or those unaware of hypoglycemia.

Study Limitations: No measurement of certain outcomes such as diabetes complications, death, and costs.
Population Gaps: No studies focused on pregnant women or those with hypoglycemia unawareness.